Riskpilot← Back to searchSign inGet full accessPharmaSultant AB
ABActiveOrg 5590455910Pilåkersvägen 42Business and other management consultancy activities · NACE 7020Est. 20161 employees
Revenue 2025
SEK 0
EBITDA margin
—
+20% vs 2024
Equity ratio
23.0%
Financial strength
Net profit 2025
SEK -22K
+12% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -20K | +20% |
| Net profit | SEK -22K | +12% |
| Total assets | SEK 1,3M | -2% |
| Equity | SEK 289K | -7% |
| Employees | 1 | — |
Legal name
PharmaSultant AB
Org number
5590455910
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
4 januari 2016
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva konsultverksamhet inom ramen för farmaceutisk industri ävensom idka annan därmed förenlig verksamhet.
Address
Pilåkersvägen 42
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 628 | 287 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 681 | −43 | −59 | −25 | −20 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 1 681 | −43 | −59 | −25 | −20 |
| Net financials | −1 | — | −4 | — | — |
| Profit before tax | 1 260 | 3 | −1 | −25 | −20 |
| Tax | −299 | −2 | −0 | −0 | −2 |
| Net profit | 961 | 1 | −1 | −25 | −22 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 861 | 1 756 | 1 205 | 1 278 | 1 256 |
| Equity | 1 123 | 1 124 | 936 | 311 | 289 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 318 | 292 | 19 | 717 | 717 |
| Total debt | 318 | 292 | 19 | 717 | 717 |
EBITDA margin
-2000000.0%
This company
15.8%
Market median
-12658328% vs market
20212025
Equity ratio
23.0%
This company
38.2%
Market median
-40% vs market
20212025
Return on equity
-7.6%
This company
18.4%
Market median
-141% vs market
20212025
Net profit margin
-2200000.0%
This company
8.1%
Market median
-27160594% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
3.35×
This company
0.62×
Market median
-440% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Hvistendal Holding AB
PharmaSultant AB Board members of PharmaSultant AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Märta Susanne Tang Hvistendal | Deputy Board Member | 0 companies |
| Kim Tang Hvistendal | Board of Directors | 0 companies |